• Peiliang Geng, Juanjuan Ou, Jianjun Li, Yunmei Liao, Ning Wang, Rina Sa, Lisha Xiang, and Houjie Liang.
• From the Department of Oncology and Southwest Cancer Center, Southwest Hospital Third Military Medical University, Chongqing, China.
• Medicine (Baltimore). 2015 Aug 1; 94 (31): e1024e1024.

AbstractSeveral epidemiological studies have focused on the role of nuclear factor-kappa-B inhibitor-alpha (NFKBIA) -881 A>G polymorphism in cancer susceptibility. However, the published data have led to contentious results. This study was designed to examine the association between -881 A>G polymorphism and cancer risk.Comprehensive search of PubMed, Web of science and Embase, identified a total of 5 case-control studies. To assess the association, comparison among all subjects plus subgroup analysis by ethnicity was performed and odds ratio (OR) along with 95% confidence interval (CI) was calculated with the fixed-effect model or the random-effects model dependent on the heterogeneity.The pooling data consisting of 1965 cancer cases and 2717 cancer-free controls demonstrated no significant association with overall cancer risk. However, the subgroup of Asian populations showed statistical evidence for an increase in risk of cancer (GG vs. AA, OR, 2.14; 95% CI, 1.03-4.46; GG + GA vs. AA, OR, 1.22; 95% CI, 1.01-1.47; GG vs. GA + AA, OR, 2.09; 95% CI, 1.01-4.34).This investigation on the association of -881 A>G polymorphism and cancer susceptibility reveals that -881 A>G polymorphism may act as a candidate for cancer development in Asian populations.

19 keywords...

hide…